title: [Safety and adverse event profiling of pegylated L-asparaginase combined chemotherapy in the treatment of lymphoma].
abstract: OBJECTIVE
  To analyze the safety and adverse event profiling of pegylated L-asparaginase (PEG-asp) combined chemotherapy in the treatment of lymphoma patients.
  
  
  METHODS
  The clinical data of 32 lymphoma patients on PEG-asp-based chemotherapy from January 2008 to March 2012 were retrospectively collected and analyzed.
  
  
  RESULTS
  There were 22 males and 10 females with a median age of 40 years. They were diagnosed as NK/T cell lymphoma (n = 22) and lymphoblastic lymphoma (n = 10). The overall response rate was 71.9% (23/32). And complete remission was 40.6% (13/32) and partial remission 31.3% (10/32). Myelosuppression was the most common adverse event at an incidence of 81.2% (26/32). Other adverse events included a low level of fibrinogen (n = 13, 40.6%), hypoalbuminemia (n = 8, 25%) and hyperlipidemia (n = 9, 28.1%). No instance of anaphylaxis, acute pancreatitis and thrombosis occurred.
  
  
  CONCLUSIONS
  PEG-asp is both effective and safe in the treatment of lymphoma and it is well-tolerated.
authors: Peking University Cancer Hospital & Institute, Department of Lymphoma, Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education), Beijing 100142, China.
authors: Ling-yan
authors: LY
authors: Ping
authors: Wen
authors: W
authors: Zheng
authors: Xiao-pei
authors: XP
authors: Wang
authors: Yan
authors: Y
authors: Xie
authors: Ning-jing
authors: NJ
authors: Lin
authors: Mei-feng
authors: MF
authors: Tu
authors: Zhi-tao
authors: ZT
authors: Ying
authors: Chen
authors: C
authors: Zhang
authors: Wei-ping
authors: WP
authors: Liu
authors: Li-juan
authors: LJ
authors: Deng
authors: Jun
authors: J
authors: Zhu
authors: Yu-qin
authors: YQ
authors: Song
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D001215:Asparaginase